3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Pituitary Neoplasms
7
Neuroendocrine Tumors
6
Carcinoid Tumor
5
Acromegaly
5
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Gastro-enteropancreatic neuroendocrine tumor
3
Pituitary ACTH Hypersecretion
2
Neoplasms
2
Neoplasm Metastasis
2
Nelson Syndrome
2
Multiple Myeloma
2
Liver Neoplasms
2
Growth Disorders
2
Gigantism
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Hepatocellular
2
ACTH Syndrome, Ectopic
2
Uveal Melanoma
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Serotonin Syndrome
1
Sarcoma, Synovial
1
Prolactinoma
1
Prolactin-Producing Pituitary Tumor
1
Primary Inoperable Thymoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Pancreatic Fistula
1
Neuroectodermal Tumors, Primitive
1
Interventions
Doxorubicin
17
Cyclophosphamide
15
Ifosfamide
11
fludarabine
8
Radiotherapy
8
tazemetostat
4
pembrolizumab
4
pazopanib
4
Gemcitabine
4
pegfilgrastim
3
cixutumumab
3
Trabectedin
3
Radiation
3
Imatinib Mesylate
3
Filgrastim
3
Docetaxel
3
Dacarbazine
3
sargramostim
2
liposomal doxorubicin
2
fludarabine phosphate
2
brostallicin
2
aldesleukin
2
X-Rays
2
Sunitinib
2
Specimen Handling
2
Sorafenib
2
Radiation Dose Hypofractionation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Leukapheresis
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma, Synovial
×
pasireotide
×
Clear all
NCT06456359
2025-01-13
PAMSARC
University Hospital Heidelberg
Phase 2
Recruiting
28 enrolled